Kinoteck Therapeutics Co. Ltd. have prepared and tested new ribosomal protein S6 kinase alpha-3 (RSK-2; MAPKAPK-1b) inhibitors potentially useful for the treatment of cancer.

Biocells (Beijing) Biotech Co. Ltd. has patented isoquinolinone derivatives acting aquaporin-4 (AQP4) inhibitors and thus reported to be useful for the treatment of hypervolemia (fluid overload) and cerebral ischemia.

Work at Zhuhai Yufan Biotechnologies Co. Ltd. has led to the development of proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety coupled to eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1)-targeting moiety.

Janssen R&D (Ireland) has identified compounds acting as viral fusion inhibitors and reported to be useful for the treatment of respiratory syncytial virus (RSV) infections.

A U.S. patent describes new serine/threonine-protein kinase LATS1, LATS2 and/or RAC serine/threonine-protein kinase inhibitors.

Fochon Biosciences Ltd. has discovered new apoptosis regulator Bcl-2 inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified haloindole macrocyclic compounds acting as GTPase KRAS (G12C mutant) inhibitors and thus reported to be useful for the treatment of cancer.

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented new NLRP3 inflammasome inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, Parkinson’s and Alzheimer’s diseases.

New 5’-nucleotidase (CD73) inhibitors have been reported by Adorx Therapeutics Ltd. as potentially useful for the treatment of cancer.

A Lysoway Therapeutics Inc. patent describes sulfonyl cyclic derivatives acting as mucolipin-1 (MCOLN1; TRPML1) activators.